Substitute cost disadvantage ‘unjust’

Pharmacy body raises concerns that Actemra substitution issues will impact affordability and equity of access The PSA has raised concerns about the news that community pharmacists are now able to substitute tocilizumab (Actemra) formulations without prior prescriber approval due to serious shortages. Under the new Serious Scarcity Substitution Instrument (SSSI) for Actemra, the 162 mg/0.9

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous COVID vax booster program likely
Next World news wrapup: 12 August 2021